Alkali Burn Treated with 2% Rebamipide Ophthalmic Suspension: A Case Report

Sasaki, Hidenori; Kokubun, Takamichi

doi:10.1159/000369201

Cited by 5 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 8 – 11 Rebamipide ophthalmic suspension has been reported to exhibit multiple pharmacological effects, such as promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, 8 , 9 restoring the barrier function of the corneal epithelium, 12 , 13 and anti-inflammatory activity. 14 It has been reported that rebamipide ophthalmic suspension is effective not only for dry eyes but also for other corneal diseases such as Sjögren’s syndrome, 15 persistent corneal erosion, 16 superficial limbic keratopathy, 17 alkaline corneal injury, 18 lid wiper epitheliopathy, 19 and lagophathalmos. 20 However, no reports have been published concerning the efficacy of rebamipide ophthalmic suspension for persistent corneal epithelial defects associated with diabetic keratopathy.…”

Section: Introductionmentioning

confidence: 99%

Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes

Hayashi

Toshida

Matsuzaki

et al. 2016

IMCRJ

View full text Add to dashboard Cite

ObjectiveRebamipide ophthalmic suspension was developed for the treatment of dry eyes and for other corneal diseases, promoting the secretion of both mucin in tear fluid and membrane-associated mucin, increasing the number of goblet cells, and restoring the barrier function of the corneal epithelium. We report a case of a persistent corneal epithelial defect in a patient with diabetes treated with topical application of rebamipide ophthalmic suspension.Case presentationA 73-year-old woman had a history of type 2 diabetes for 35 years and nonproliferative diabetic retinopathy for 23 years. She presented to our department with discharge and ophthalmalgia in the left eye. A corneal ulcer was detected, and culture of corneal scrapings was performed, with Staphylococcus aureus and Streptococcus canis being isolated. The infection was treated with levofloxacin eye drops and ofloxacin ophthalmic ointment based on the sensitivity profile of the isolate. However, a corneal epithelial defect persisted for approximately 2 months despite continuing treatment with 0.1% hyaluronic acid ophthalmic suspension and 0.3% ofloxacin eye ointment. Her hemoglobin A1c was 7.3%. The persistent corneal epithelial defect showed improvement at 2 weeks after treatment with rebamipide unit dose 2% ophthalmic suspension, and it did not recur even when vitrectomy was subsequently performed for vitreous hemorrhage due to progression of diabetic retinopathy.ConclusionThis is the first report about efficacy of rebamipide unit dose 2% ophthalmic suspension for presenting persistent corneal epithelial defect in a patient with diabetes. In the present case, the suggested mechanisms are the following: improving the corneal barrier function, stabilization of mucin on the keratoconjunctival epithelium, and improving the wettability and stability of the tear film, which resulted in the promotion of healing of the corneal epithelial defect in a short time period.

show abstract